4[4]Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long - acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.Diabetes,2000,49(12): 2142 ～2148
5K. Hermansen,P. Fontaine,K. K. Kukolja,V. Peterkova,G. Leth,M.-A. Gall. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes[J] 2004,Diabetologia(4):622～629
6Ole ?sterberg,Lars Erichsen,Steen H. Ingwersen,Anne Plum,Henrik E. Poulsen,Paolo Vicini. Pharmacokinetic and Pharmacodynamic Properties of Insulin Aspart and Human Insulin[J] 2003,Journal of Pharmacokinetics and Pharmacodynamics(3):221～235
